SELLAS Reports No Revenue, Bolsters Capital with January Offering

TL;DR

SELLAS is burning cash with no revenue, so watch their clinical trial progress and cash runway closely after their January capital raise.

AI Summary

SELLAS Life Sciences Group, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 30, 2025, was not explicitly stated but can be inferred from the lack of revenue and ongoing operational costs. For the six months ended June 30, 2025, the net loss was also not explicitly stated, indicating continued investment in research and development. A key business change was the January 2025 Registered Direct Offering, which involved the issuance of common stock and pre-funded warrants, impacting the company's capital structure. This offering likely provided capital for ongoing clinical trials and operations. Risks include the inherent uncertainties of clinical development and the need for additional financing, as evidenced by the capital raise. The strategic outlook remains focused on advancing its pipeline, particularly given its pharmaceutical preparations SIC code, which requires significant R&D investment.

Why It Matters

For investors, SELLAS's continued lack of revenue underscores its pre-commercial stage, making clinical trial progress and cash burn critical metrics. The January 2025 Registered Direct Offering, while dilutive, provided essential capital for ongoing operations and drug development, which is crucial for a company in the pharmaceutical preparations sector competing against larger, revenue-generating biotechs. Employees' job security is tied to successful clinical outcomes and sustained funding. Customers, primarily future patients, depend on the company's ability to bring new therapies to market. The broader market watches such offerings as indicators of investor confidence in early-stage biotech, impacting sector sentiment.

Risk Assessment

Risk Level: high — The risk level is high due to SELLAS Life Sciences Group, Inc.'s complete lack of revenue for the three and six months ended June 30, 2025, indicating a pre-commercial stage company heavily reliant on external financing. The January 2025 Registered Direct Offering, while providing capital, also highlights the ongoing need for funding to support its pharmaceutical development pipeline.

Analyst Insight

Investors should closely monitor SELLAS's clinical trial milestones and cash burn rate. Given the pre-revenue status, any significant delays in trials or further dilutive financing events could severely impact shareholder value.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• 2025-01-29 — Date of January 2025 Registered Direct Offering (when common stock and pre-funded warrants were issued)

Key Players & Entities

• SELLAS Life Sciences Group, Inc. (company) — filer of the 10-Q
• January 2025 Registered Direct Offering (event) — capital raise event
• Galena Biopharma, Inc. (company) — former company name of SELLAS
• RXi Pharmaceuticals Corp (company) — former company name of SELLAS
• Bloomberg (company) — publisher of the analysis

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company has historically incurred net losses and has no revenue, necessitating significant ongoing investment in research and development. The January 2025 Registered Direct Offering indicates a need for capital to fund operations and clinical trials, and future financing will likely be required to support continued development and potential commercialization.
• Clinical Development Risks [high — operational]: As a company in the pharmaceutical preparations sector, SELLAS Life Sciences Group is subject to the inherent uncertainties and risks associated with clinical trials. Success in drug development is not guaranteed, and delays or failures in clinical trials can significantly impact the company's prospects and financial condition.
• Regulatory Approval Uncertainty [high — regulatory]: The pharmaceutical industry is heavily regulated. Obtaining approval from regulatory bodies like the FDA is a complex and lengthy process. Any delays or failure to obtain necessary approvals for its drug candidates would materially adversely affect the company's business and financial condition.

Industry Context

SELLAS Life Sciences Group operates within the pharmaceutical preparations sector, characterized by intensive research and development, long product development cycles, and stringent regulatory oversight. The industry is highly competitive, with numerous companies vying for market share and significant investment required to bring new therapies to market. Trends include a focus on novel drug discovery, personalized medicine, and the increasing complexity of clinical trials.

Regulatory Implications

As a pharmaceutical company, SELLAS is subject to extensive regulation by bodies such as the FDA. The development and approval process for new drugs is rigorous and time-consuming, posing significant risks. Compliance with Good Manufacturing Practices (GMP) and other regulatory standards is critical throughout the product lifecycle.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates.
2. Assess future financing needs and dilution potential.
3. Review cash burn rate and runway.

Key Dates

• 2025-01-29: Registered Direct Offering — The company issued common stock and pre-funded warrants, raising capital likely to fund ongoing operations, clinical trials, and research and development activities.
• 2025-06-30: Quarter End — Marks the end of the second quarter for which financial results are reported, showing no revenue and continued investment in R&D.

Glossary

Registered Direct Offering

A type of public offering where a company sells newly issued securities directly to a select group of investors, often institutional buyers, rather than through an underwriter. (Indicates a capital raise event that impacts the company's share structure and provides funds for operations.)

Pre-funded Warrants

Warrants that allow the holder to purchase shares of common stock at a nominal exercise price, effectively acting as a substitute for immediate stock purchase. (These were issued as part of the January 2025 offering, affecting the company's capital structure and potential future dilution.)

Pharmaceutical Preparations

A standard industrial classification code (SIC) for companies involved in the manufacturing of drugs and medicines. (Defines SELLAS's industry, highlighting its focus on drug development and the associated high R&D investment and regulatory hurdles.)

Year-Over-Year Comparison

The financial reporting for the three and six months ended June 30, 2025, shows no revenue, mirroring the performance in the comparable periods of the prior year. This consistency in zero revenue underscores the company's pre-commercial status. While specific net loss figures for the current periods are not explicitly detailed, the ongoing operational costs and R&D investments imply continued losses. The key change noted is the January 2025 Registered Direct Offering, which was not a feature of the prior year's reporting, indicating a significant capital-raising event to support its pipeline development.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share SLS The Nasdaq Stoc

Filing Documents

• sls-20250630.htm (10-Q) — 685KB
• sls-20250630ex101.htm (EX-10.1) — 59KB
• sls-20250630ex311.htm (EX-31.1) — 8KB
• sls-20250630ex312.htm (EX-31.2) — 8KB
• sls-20250630ex321.htm (EX-32.1) — 6KB
• sls-20250630ex322.htm (EX-32.2) — 6KB
• sls-20250630_g1.jpg (GRAPHIC) — 30KB
• 0001390478-25-000016.txt ( ) — 4102KB
• sls-20250630.xsd (EX-101.SCH) — 33KB
• sls-20250630_cal.xml (EX-101.CAL) — 37KB
• sls-20250630_def.xml (EX-101.DEF) — 111KB
• sls-20250630_lab.xml (EX-101.LAB) — 437KB
• sls-20250630_pre.xml (EX-101.PRE) — 293KB
• sls-20250630_htm.xml (XML) — 438KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1 Financial Statements 4 Unaudited Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 4 Unaudited Consolidated Statements of Operations for the Three and Six Months Ended June 3 0 , 2025 and 2024 5 Unaudited Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 6 Unaudited Consolidated Statements of Cash Flows for the Six Months Ended June 30 , 2025 and 2024 8 Unaudited Notes to Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations 19

Quantitative and Qualitative Disclosures About Market Risk

Item 3 Quantitative and Qualitative Disclosures About Market Risk 28

Controls and Procedures

Item 4 Controls and Procedures 28

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings 29

Item 1 Legal Proceedings 29

Risk Factors 29

Item 1A Risk Factors 29

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 29

Defaults Upon Senior Securities

Item 3 Defaults Upon Senior Securities 29

Mine Safety Disclosures

Item 4 Mine Safety Disclosures 29

Other Information

Item 5 Other Information 29

Signatures

Signatures The names "SELLAS Life Sciences Group, Inc.," "SELLAS," the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies. Unless the context otherwise indicates, references in these notes to the "Company," "we," "us" or "our" refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. 1 SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words "expect," "intend," "plan," "believe," "project," "estimate," "may," "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements and include, without limitation, statements regarding: our future financial and business performance; strategic plans for our business and product candidates; our ability to develop or commercialize products; the expected results and timing of clinical trials and nonclinical studies; our ability to comply with the terms of our license agreements; developments and projections relating to our competitors and industry; our expectations regarding our ability to obtain, develop and maintain intellectual property protection and not infringe on the righ

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share data) (Unaudited) June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 25,297 $ 13,886 Restricted cash and cash equivalents 100 100 Prepaid expenses and other current assets 4,050 2,341 Total current assets 29,447 16,327 Operating lease right-of-use assets 683 925 Goodwill 1,914 1,914 Deposits and other assets 261 266 Total assets $ 32,305 $ 19,432 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 3,336 $ 3,500 Accrued expenses and other current liabilities 2,083 5,466 Operating lease liabilities 580 544 Total current liabilities 5,999 9,510 Operating lease liabilities, non-current 157 457 Total liabilities 6,156 9,967 Commitments and contingencies (Note 5) Stockholders' equity: Common stock, $ 0.0001 par value; 350,000,000 shares authorized, 100,367,113 and 73,977,459 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 10 7 Additional paid-in capital 286,678 257,583 Accumulated deficit ( 260,539 ) ( 248,125 ) Total stockholders' equity 26,149 9,465 Total liabilities and stockholders' equity $ 32,305 $ 19,432 See accompanying notes to these unaudited consolidated financial statements. 4 Table of Contents SELLAS LIFE SCIENCES GROUP, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except share and per share data) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 3,871 $ 5,186 $ 7,076 $ 10,297 General and administrative 3,002 2,435 5,860 6,969 Total operating expenses 6,873 7,621 12,936 17,266 Loss from operations ( 6,873 ) ( 7,621 ) ( 12,936 ) ( 17,266 ) Non-operating income: Interest income 272 151 522 230 Total non-operating income 272 151 522 230 Net loss $ ( 6,601 ) $ ( 7,470 ) $ ( 12

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) 1. Organization and Description of Business Overview SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on novel therapeutics for a broad range of cancer indications. SELLAS' lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in an array of tumor types. SELLAS' second product candidate is SLS009 (tambiciclib), a small molecule, highly selective cyclin-dependent kinase 9 ("CDK9") inhibitor, which the Company licensed from GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau and Taiwan ("SLS009 Territory"). Each of GPS and SLS009 has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. 2. Liquidity and Going Concern Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of June 30, 2025, has an accumulated deficit of $ 260.5 million. During the six months ended June 30, 2025, the Company incurred a net loss of $ 12.4 million, and used $ 16.4 million of cash in operations. The Company expects to continue to generate operating losses and negative cash flows from operations for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure. On January 29, 2025, the Company consummated a registered direct offering (the "January 2025 Registered Direct Offering") with an

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued (Unaudited) As of June 30, 2025, the Company had cash and cash equivalents of approximately $ 25.3 million and restricted cash and cash equivalents of $ 0.1 million. In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of Financial Statements - Going Concern , the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents will not be sufficient to fund its current planned operations for at least the next twelve months from the date of issuance of these consolidated financial statements. The Company will require substantial additional financing to commercially develop any current or future product candidates. If the Company is unable to obtain additional funding on a timely basis, it will be required to scale back its plans and place certain activities on hold. The Company currently does not have any commitments to obtain additional funds. The Company's management continues to evaluate different strategies to obtain the required funding for future operations. These strategies may include public and private placements of equity and/or debt securities, as well as payments from potential strategic research and development collaborations or licensing and/or marketing arrangements with pharmaceutical companies. Additionally, the Company continues to pursue discussions with global and regional pharmaceutical companies for licensing and/or co-development rights to the Company's product candidates. There can be no assurance that these future funding efforts will be successful. 3. Basis of Presentation and Significant Accounting Policies The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Suppleme

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued (Unaudited) allocate resources and in assessing performance. The Company's chief operating decision maker ("CODM") is the President & Chief Executive Officer. The Company views its operations and manages its business as one operating segment, which includes all activities related to the development of novel therapeutics for a broad range of cancer indications. The determination of a single reportable segment is consistent with the consolidated financial information provided to the CODM. The CODM does not evaluate discrete financial information for each of the Company's clinical product candidates, and views and manages the Company's clinical programs as one consolidated segment for which all operations are centralized. Segment profit or loss is measured as the Company's net loss as reported on the consolidated statement of operations. As the Company does not currently generate revenues, the CODM evaluates Company performance through the achievement of clinical development goals. The CODM also monitors the Company's cash and cash equivalents as reported on the consolidated balance sheet, net cash used in operations as reported on the consolidated statement of cash flows, and segment expense information in order to make operational decisions, allocate resources, and plan for future activities. Segment expenses consist of the Company's functional expenses, research and development expenses and general and administrative expenses, as reported in the consolidated statement of operations. Other segment items included in the measure of segment net loss include non-operating income, which primarily relates to interest income. The measure of total segment assets is reported on the consolidated balance sheet as total assets. The accounting policies of the Company's single reportable segment are the same as those for the consolidated financial statements described in this Note 3. Fair Value of Financial Instru

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued (Unaudited) to the fact that, when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands): Six Months Ended June 30, 2025 2024 Common stock warrant

View Full Filing

View this 10-Q filing on SEC EDGAR